Notice of Proposed Sale · 144
Erasca, Inc.
ERASNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Erasca, Inc.
- Issuer CIK
- 0001761918
- SEC file number
- 001-40602
- Phone
- 8584656511
- Person for whose account securities are to be sold
- Erasca Foundation
- Relationships to issuer
- Foundation
- Street
- 3115 MERRYFIELD ROW STE 300
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 8,333 | 157,637.52 | 310,984,542 | 07/21/2026 | NASDAQ | Merrill Lynch |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch
- Street
- 6002 El Tordo
- Street (continued)
- PO Box 7297
- City
- Rancho Santa Fe
- State / country code
- CA
- Postal code
- 92067
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/20/2021 | Donation | Erasca, Inc. | 10,193,557 | N | 07/20/2021 | Donation |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Erasca Foundation | Common | 06/15/2026 | 8,333 | 117,476.95 |
| Erasca Foundation | Common | 05/15/2026 | 8,333 | 84,528.29 |
Seller — prior-sale row 1, entry 1
- Name
- Erasca Foundation
- Street
- 3115 MERRYFIELD ROW
- Street (continued)
- STE 300
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Seller — prior-sale row 2, entry 1
- Name
- Erasca Foundation
- Street
- 3115 MERRYFIELD ROW
- Street (continued)
- STE 300
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/21/2026
- Signed
- Brian Baker
- Plan adoption dates
- 05/21/2026
Company context
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.